Segall Bryant & Hamill LLC Boosts Holdings in QuidelOrtho Co. (NASDAQ:QDEL)

Segall Bryant & Hamill LLC grew its holdings in QuidelOrtho Co. (NASDAQ:QDEL - Free Report) by 143.9% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 1,046,649 shares of the company's stock after buying an additional 617,592 shares during the quarter. QuidelOrtho makes up about 0.6% of Segall Bryant & Hamill LLC's investment portfolio, making the stock its 28th largest holding. Segall Bryant & Hamill LLC owned approximately 1.56% of QuidelOrtho worth $46,628,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the business. Vanguard Group Inc. raised its stake in QuidelOrtho by 12.6% in the fourth quarter. Vanguard Group Inc. now owns 6,817,412 shares of the company's stock worth $303,716,000 after buying an additional 764,900 shares in the last quarter. Rubric Capital Management LP grew its holdings in shares of QuidelOrtho by 15.2% during the 3rd quarter. Rubric Capital Management LP now owns 4,200,000 shares of the company's stock worth $191,520,000 after acquiring an additional 554,410 shares during the period. State Street Corp raised its position in shares of QuidelOrtho by 16.9% in the 3rd quarter. State Street Corp now owns 1,907,898 shares of the company's stock worth $87,000,000 after acquiring an additional 275,522 shares in the last quarter. FMR LLC boosted its position in shares of QuidelOrtho by 28.0% during the third quarter. FMR LLC now owns 1,256,356 shares of the company's stock valued at $57,290,000 after purchasing an additional 274,633 shares in the last quarter. Finally, American Century Companies Inc. grew its stake in QuidelOrtho by 72.6% in the fourth quarter. American Century Companies Inc. now owns 1,115,551 shares of the company's stock worth $49,698,000 after purchasing an additional 469,132 shares during the period. 99.00% of the stock is currently owned by institutional investors.

Remove Ads

Analyst Upgrades and Downgrades

QDEL has been the subject of several recent research reports. Citigroup raised QuidelOrtho from a "neutral" rating to a "buy" rating and raised their price objective for the company from $44.00 to $50.00 in a research report on Wednesday, December 11th. Jefferies Financial Group initiated coverage on shares of QuidelOrtho in a research report on Tuesday, December 10th. They set a "hold" rating and a $43.00 price target for the company. Royal Bank of Canada cut their price objective on shares of QuidelOrtho from $64.00 to $61.00 and set an "outperform" rating on the stock in a report on Thursday, February 13th. UBS Group lifted their target price on shares of QuidelOrtho from $43.00 to $45.00 and gave the company a "neutral" rating in a report on Thursday, February 13th. Finally, StockNews.com downgraded QuidelOrtho from a "buy" rating to a "hold" rating in a research note on Saturday, February 15th. Four investment analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $51.20.

QuidelOrtho Stock Down 2.7 %

NASDAQ:QDEL traded down $0.98 on Friday, reaching $34.89. 614,620 shares of the stock traded hands, compared to its average volume of 954,652. The company has a current ratio of 1.22, a quick ratio of 0.69 and a debt-to-equity ratio of 0.71. The company has a market capitalization of $2.35 billion, a price-to-earnings ratio of -1.15 and a beta of 0.10. QuidelOrtho Co. has a 12 month low of $29.74 and a 12 month high of $49.45. The company's fifty day simple moving average is $40.14 and its 200 day simple moving average is $41.42.

QuidelOrtho (NASDAQ:QDEL - Get Free Report) last announced its quarterly earnings data on Wednesday, February 12th. The company reported $0.63 earnings per share for the quarter, missing analysts' consensus estimates of $1.07 by ($0.44). QuidelOrtho had a positive return on equity of 3.78% and a negative net margin of 72.84%. Equities analysts predict that QuidelOrtho Co. will post 2.3 EPS for the current fiscal year.

QuidelOrtho Profile

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.